Chemokine-protease interactions in cancer

被引:61
作者
Van Damme, J
Struyf, S
Opdenakker, G
机构
[1] Univ Louvain, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium
[2] Univ Louvain, Rega Inst Med Res, Immunobiol Lab, B-3000 Louvain, Belgium
关键词
angiogenesis; chemokines; dipeptidyl peptidase IV; metalloproteinase; tumour;
D O I
10.1016/j.semcancer.2003.10.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Solid tumour and leukemic cells expressing chemokine receptors, metastasize to chemokine-secreting organs. Chemokines indirectly affect tumour development by attracting immunocompetent cells with pro- or anti-tumoral activities. Various membrane-associated and soluble proteases selectively cleave specific chemokines. Precursor plasma chemokines (CXCL7, CCL14) need to be proteolytically processed to obtain receptor affinity. Angiogenic CXC chemokines (CXCL1, CXCL8) have increased CXCR1/CXCR2 affinity after limited NH2-terminal processing, whereas truncated angiostatic chemokines (CXCL10) show lower CXCR3 affinity without loss of angiostatic potential. NH2-terminally cleaved monocyte chemotactic proteins (CCL2, CCL7, CCL8) have impaired capacity to attract tumour-associated macrophages and function as receptor antagonists for intact CC chemokines. Migration of Th1/CCR5(+) and Th2/CCR4(+) effector lymphocytes toward CCR5 (CCL5, CCL3L1) and CCR4 (CCL22) ligands is affected by cleavage. Although proteolytical processing of chemokines is well studied in vitro, the direct or indirect effects on tumour invasion and metastasis are only poorly evaluated. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:201 / 208
页数:8
相关论文
共 81 条
[51]   Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties [J].
Proost, P ;
Schutyser, E ;
Menten, P ;
Struyf, S ;
Wuyts, A ;
Opdenakker, G ;
Detheux, M ;
Parmentier, M ;
Durinx, C ;
Lambeir, AM ;
Neyts, J ;
Liekens, S ;
Maudgal, PC ;
Billiau, A ;
Van Damme, J .
BLOOD, 2001, 98 (13) :3554-3561
[52]   Amino-terminal truncation of chemokines by CD26/dipeptidylpeptidase IV - Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection [J].
Proost, P ;
De Meester, I ;
Schols, D ;
Struyf, S ;
Lambeir, AM ;
Wuyts, A ;
Opdenakker, G ;
De Clercq, E ;
Scharpe, S ;
Van Damme, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (13) :7222-7227
[53]   PURIFICATION OF MELANOMA GROWTH STIMULATORY ACTIVITY [J].
RICHMOND, A ;
THOMAS, HG .
JOURNAL OF CELLULAR PHYSIOLOGY, 1986, 129 (03) :375-384
[54]   CLONING AND EXPRESSION OF THE RECEPTOR FOR HUMAN UROKINASE PLASMINOGEN-ACTIVATOR, A CENTRAL MOLECULE IN CELL-SURFACE, PLASMIN DEPENDENT PROTEOLYSIS [J].
ROLDAN, AL ;
CUBELLIS, MV ;
MASUCCI, MT ;
BEHRENDT, N ;
LUND, LR ;
DANO, K ;
APPELLA, E ;
BLASI, F .
EMBO JOURNAL, 1990, 9 (02) :467-474
[55]  
Schönbeck U, 1998, J IMMUNOL, V161, P3340
[56]   Recombinant mouse granulocyte chemotactic protein-2: Production in bacteria, characterization, and systemic effects on leukocytes [J].
Starckx, S ;
Wuyts, A ;
Opsomer, I ;
Van Coillie, E ;
Proost, P ;
Arnold, B ;
Van Damme, J ;
Opdenakker, G .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2002, 22 (09) :965-974
[57]   THE FUNCTIONAL-ROLE OF THE ELR MOTIF IN CXC CHEMOKINE-MEDIATED ANGIOGENESIS [J].
STRIETER, RM ;
POLVERINI, PJ ;
KUNKEL, SL ;
ARENBERG, DA ;
BURDICK, MD ;
KASPER, J ;
DZUIBA, J ;
VANDAMME, J ;
WALZ, A ;
MARRIOTT, D ;
CHAN, SY ;
ROCZNIAK, S ;
SHANAFELT, AB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (45) :27348-27357
[58]  
Struyf S, 1998, J IMMUNOL, V161, P2672
[59]  
Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO
[60]  
2-G